Abstract
The objective of this paper is to analyse the potential therapeutic action of MMP inhibitors in the management of osteoarthritis (OA), based on a critical review of the literature. The role played by metalloproteinases (MPs) in the pathophysiology of osteoarthritis is discussed, as well as their regulation by tissular inhibitors, activators and cytokines. The evidences that commonly used drugs for treating osteoarthritis are also active on MPs synthesis is also reported. Finally, this paper provides an analysis of the recent patents published with promising therapeutic potential and gives new perspectives for anti-MPs therapy.